Orum Therapeutics, Inc.
Financials
Valuation Metrics
Orum Therapeutics, Inc.'s Market Cap is ₩8136B. At end of 2025 it was ₩2.6T. Ranked #341 of 2,421 in KR market (top 14%), #100 of 1,640 on KOSDAQ (top 6%), #37 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 16%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 813.56B KRW | KR#341/2,421 Sec#37/231 |
| Revenue | 40.6M KRW | KR#2,394/2,421 Sec#225/231 |
| Net Income | 18.51B KRW | KR#731/2,421 Sec#48/231 |
| Total Assets | 169.32B KRW | KR#1,424/2,421 Sec#108/231 |
| Net Assets | 130.89B KRW | KR#1,225/2,421 Sec#93/231 |
| Employees | 21 | KR#2,247/2,421 Sec#212/231 |
| Value | ||
| P/E | 43.95x | KR#1,393/2,421 Sec#88/231 |
| P/B | 6.22x | KR#2,286/2,421 Sec#196/231 |
| P/S | 34525.17x | KR#2,415/2,421 Sec#229/231 |
| Profitability | ||
| ROE | 14.14% | KR#362/2,421 Sec#25/231 |
| ROA | 10.93% | KR#229/2,421 Sec#18/231 |
| Op. Margin | -161817.85% | KR#2,395/2,421 Sec#226/231 |
| Revenue Growth | -99.89% | KR#2,329/2,421 Sec#212/231 |
| Financial Health | ||
| Debt Ratio | 29.37% | KR#573/2,421 Sec#65/231 |
| Total Debt | 12.40B KRW | KR#1,555/2,421 Sec#137/231 |
| Cash | 4.07B KRW | KR#2,083/2,421 Sec#193/231 |
| Performance | ||
| 1Y Return | 7.32% | KR#608/2,421 Sec#39/231 |
| 1M Return | -46.80% | KR#2,374/2,421 Sec#228/231 |
| From 52W High | -74.49% | KR#2,280/2,421 Sec#199/231 |
| 1Y MDD | -73.97% | KR#2,141/2,421 Sec#189/231 |
| Trading | ||
| Volume | 29,881 shares | KR#1,379/2,421 Sec#135/231 |
| Trading Value | 1.12B KRW | KR#684/2,421 Sec#69/231 |
| Foreign Own. | 7.04% | KR#634/2,421 Sec#55/231 |
| Per Share | ||
| EPS | 851 KRW | KR#785/2,421 Sec#56/231 |
| BPS | 6,017 KRW | KR#1,355/2,421 Sec#95/231 |
Company Info
Orum Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic solutions for both cancer and immune system conditions. The firm specializes in creating degrader-antibody conjugates, an innovative class of drugs that merges traditional antibody-drug conjugate (ADC) technology with targeted protein degradation. Their flagship product candidate, ORM-1153, functions as a GSPT1 protein degrader, specifically engineered to address hematologic malignancies. Orum Therapeutics was established in 2016 and operates out of Daejeon, South Korea.